Chloramphenicol

Trachoma, Dacryocystitis, Bacterial diarrhoea + 15 more

Treatment

4 FDA approvals

10 Active Studies for Chloramphenicol

What is Chloramphenicol

Chloramphenicol

The Generic name of this drug

Treatment Summary

Chlortetracycline is an antibiotic used to treat bacterial infections. It was initially discovered in 1947 in the cultures of a type of bacteria called Streptomyces venequelae, and is now produced synthetically. Chlortetracycline works by blocking the ability of bacteria to create proteins, and is mainly used to slow down the growth of bacterial cells.

Chloromycetin Otic

is the brand name

image of different drug pills on a surface

Chloramphenicol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Chloromycetin Otic

Chloramphenicol

1953

6

Approved as Treatment by the FDA

Chloramphenicol, otherwise known as Chloromycetin Otic, is approved by the FDA for 4 uses including Acne and Bacterial Infections .

Acne

Used to treat Acne in combination with Allantoin

Bacterial Infections

Acne Vulgaris

Used to treat Acne in combination with Allantoin

Urinary Tract Infection (UTI)

Effectiveness

How Chloramphenicol Affects Patients

Chloramphenicol is an antibiotic that can fight many different types of bacteria. It was originally derived from a type of bacteria, but is now made synthetically. Unfortunately, it can have dangerous side effects in humans, so it is usually only used to treat serious infections such as typhoid fever. Chloramphenicol works by preventing bacteria from making proteins and stopping their growth.

How Chloramphenicol works in the body

Chloramphenicol is able to penetrate the bacterial cell wall and attach itself to the ribosome. This prevents the ribosome from making proteins, which in turn stops the bacteria from reproducing.

When to interrupt dosage

The advocated dose of Chloramphenicol is contingent upon the diagnosed issue, such as Keratitis, Bacterial diarrhoea and Communicable Diseases. The measure fluctuates, depending on the method of delivery featured in the table beneath.

Condition

Dosage

Administration

Conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Postoperative

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Allergic Conjunctivitis (AC)

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Bacterial conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Trachoma

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Dacryocystitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Acne Vulgaris

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Blepharitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Urinary Tract Infection (UTI)

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Conjunctivitis, Bacterial

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

bacterial corneal ulcers

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

swelling of the eyes

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Communicable Diseases

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Disinfection

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Keratitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Bacterial diarrhoea

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Warnings

Chloramphenicol Contraindications

Condition

Risk Level

Notes

prophylaxis of infection in minor cuts, scrapes, or burns

Do Not Combine

Communicable Diseases

Do Not Combine

There are 20 known major drug interactions with Chloramphenicol.

Common Chloramphenicol Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Chloramphenicol.

Abetimus

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abetimus.

Chloramphenicol Toxicity & Overdose Risk

In mice, the lowest toxic dose of a drug is 1500mg/kg, and 2500mg/kg in rats. Severe reactions, known as the gray syndrome, have been reported in premature and newborn babies. These reactions include a distended abdomen with or without vomiting, a pale blue skin color, and irregular breathing, leading to death in a few hours.

image of a doctor in a lab doing drug, clinical research

Chloramphenicol Novel Uses: Which Conditions Have a Clinical Trial Featuring Chloramphenicol?

41 active clinical trials are presently investigating the potential of Chloramphenicol to reduce Inflammation of the Anterior Eye Segment, Corneal Inflammation and Superficial Ocular Infections.

Condition

Clinical Trials

Trial Phases

Allergic Conjunctivitis (AC)

1 Actively Recruiting

Phase 2

Conjunctivitis

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Blepharitis

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

swelling of the eyes

0 Actively Recruiting

Bacterial diarrhoea

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Dacryocystitis

0 Actively Recruiting

Trachoma

1 Actively Recruiting

Phase 4

Conjunctivitis

0 Actively Recruiting

bacterial corneal ulcers

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Postoperative

3 Actively Recruiting

Not Applicable, Early Phase 1

Keratitis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Disinfection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Patient Q&A Section about chloramphenicol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is chloramphenicol a strong antibiotic?

"Chloramphenicol is a broad spectrum antibiotic that kills a variety of bacteria. However, it is not commonly used because it can be toxic to the bone marrow."

Answered by AI

What bacteria does chloramphenicol treat?

"The medication chloramphenicol can be used to treat infections caused by S. typhi, H. influenzae, E. coli, Neisseria species, Staphylococcus and Streptococcus species, Rickettsia, and lymphogranuloma-psittacosis group of organisms."

Answered by AI

What is chloramphenicol used for?

"Chloramphenicol is used to treat serious infections in different parts of the body. It is sometimes given with other antibiotics. However, chloramphenicol should not be used for colds, flu, other virus infections, sore throats or other minor infections, or to prevent infections."

Answered by AI

Why is chloramphenicol toxic to humans?

"The main side effect of chloramphenicol is damage to the blood. In all animals that have been studied, it directly and consistently causes bone marrow depression, resulting in low levels of red blood cells, white blood cells, and platelets."

Answered by AI

Clinical Trials for Chloramphenicol

Image of University of North Carolina in Chapel Hill, United States.

BLTR vs B-RAP for Trichiasis

18+
All Sexes
Chapel Hill, NC

The primary objective of this randomized clinical trial is to determine whether repeat trichiasis surgery performed with Bevel-Rotate Advancement Procedure (B-RAP) improves surgical success compared to Bilamellar Tarsal Rotation (BLTR) among a group of 8-10 TT surgeons in Tanzania. The study aims to enroll 1,000 individuals with PTT. The primary outcome is repeat PTT within one year after surgery. Additionally, the study will assess eyelid contour abnormalities and how they change over a two-year period as well as patient reported outcomes. If this project is successful in improving surgical outcomes, it could change the approach to treating PTT globally. Individuals with trichiasis have a significantly reduced quality of life; correcting their trichiasis long-term has the potential to improve their quality of life and their family members' quality of life considerably.

Waitlist Available
Has No Placebo

University of North Carolina

Emily Gower, PhD

Image of University of Virginia in Charlottesville, United States.

Methadone vs Remifentanil for Pain in Craniotomy Surgery

18 - 65
All Sexes
Charlottesville, VA

Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality. Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively. In a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery. IV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery. The investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.

Phase < 1
Waitlist Available

University of Virginia

Have you considered Chloramphenicol clinical trials?

We made a collection of clinical trials featuring Chloramphenicol, we think they might fit your search criteria.
Go to Trials
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Phase 4
Recruiting

University of Missouri

Kevin M Klifto, DO, PharmD

Have you considered Chloramphenicol clinical trials?

We made a collection of clinical trials featuring Chloramphenicol, we think they might fit your search criteria.
Go to Trials